

17. A compound as defined in any one of claims 1 to 15, for use in the treatment of the human or animal body by therapy.

5 18. A compound as defined in any one of claims 1 to 15 for use in the treatment or prevention of an RSV infection.

19. Use of a compound as defined in any one of claims 1 to 15, in the manufacture of a medicament for use in the treatment or prevention of an RSV infection

10

20. A product containing:

(a) a compound as defined in any one of claims 1 to 15; and

(b) one or more further therapeutic agents;

15 for simultaneous, separate or sequential use in the treatment of a subject suffering from or susceptible to an RSV infection.

21. A product according to claim 20, wherein the further therapeutic agent is :

(i) a RSV nucleocapsid(N)-protein inhibitor;

20 (ii) another protein inhibitor, such as one that inhibits the phosphoprotein (P) protein and/or large (L) protein;

(iii) an anti-RSV monoclonal antibody, such as an F-protein antibody;

(iv) an immunomodulating toll-like receptor compound;

25 (v) another respiratory virus anti-viral, such as an anti-influenza and/or anti-rhinovirus compound; and/or

(vi) an anti-inflammatory compound.

22. A pharmaceutical composition which comprises (a) a compound as defined in any one of claims 1 to 15, and (b) one or more further therapeutic agents, as defined in claim 20 or 21, together with a pharmaceutically acceptable carrier or diluent.

30